SCHEMBL5737640

SCHEMBL5737640

CC(C)(C)OC(=O)N(CCCCO)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.54
HDAC3 O15379 2/20 0.54
HDAC2 Q92769 2/20 0.54
NCOR2 Q9Y618 1/20 0.54
L3MBTL1 Q9Y468 4/20 0.48
CTSL P07711 2/20 0.48
CTSB P07858 2/20 0.48
CTSS P25774 2/20 0.48
REN P00797 1/20 0.45
HDAC6 Q9UBN7 2/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
AKT1 P31749 2/20 0.44
CA14 Q9ULX7 1/20 0.44
SSTR4 P31391 1/20 0.44
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7983340 0.99 HDAC1 (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7973240 0.99 HDAC1 (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL1848202 0.96 HDAC1 (0.52) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7982368 0.92 REN (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7972070 0.92 REN (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7982499 0.92 REN (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7983610 0.92 REN (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL7986481 0.92 REN (0.53) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL8525848 0.92 HDAC3 (0.56) HDAC1HDAC3HDAC2NCOR2L3MBTL1
SCHEMBL8021840 0.90 HDAC3 (0.55) HDAC1HDAC3HDAC2NCOR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
EP-1549309-A4 SOMATOSTATIN ANALOGUE COMPOUNDS CHEMBRIDGE RES LAB INC (US) 2006-05-17 EP disclosed
EP-1549309-A2 SOMATOSTATIN ANALOGUE COMPOUNDS ChemBridge Research Laboratories, Inc. (US) 2005-07-06 EP disclosed
US-6872827-B2 Somatostatin analogue compounds CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2005-03-29 US disclosed
US-20040019069-A1 Somatostatin analogue compounds CHEMBRIDGE CORPORATION 2004-01-29 US disclosed
WO-2003090677-A2 SOMATOSTATIN ANALOGUE COMPOUNDS CHEMBRIDGE RESEARCH LAB., LLC (US) 2003-11-06 WO disclosed
US-6214833-B1 MADE BY ACYLATION ZAMBON GROUP S.P.A. (IT) 2001-04-10 US disclosed
US-6114394-A Polyamine derivatives as radioprotective agents MERRELL PHARMACEUTICALS INC. (US) 2000-09-05 US disclosed
EP-0686142-B1 POLYAMINE DERIVATIVES AS RADIOPROTECTIVE AGENTS MERRELL PHARMA INC (US) 1998-12-30 EP disclosed
WO-1998043972-A1 PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY ZAMBON GROUP S.P.A. (IT) 1998-10-08 WO disclosed
EP-0399519-B1 Potentiating cell-mediated immunity utilizing polyamine derivatives MERRELL PHARMA INC (US) 1996-08-07 EP disclosed
EP-0686142-A1 POLYAMINE DERIVATIVES AS RADIOPROTECTIVE AGENTS MERRELL PHARMACEUTICALS INC. (US) 1995-12-13 EP disclosed
EP-0662829-A1 POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS MERRELL PHARMACEUTICALS INC. (US) 1995-07-19 EP disclosed
WO-1994019311-A1 POLYAMINE DERIVATIVES AS RADIOPROTECTIVE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-09-01 WO disclosed
WO-1994007480-A1 POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-04-14 WO disclosed
EP-0277635-B1 Novel polyamine derivatives MERRELL DOW PHARMA (US) 1994-01-05 EP disclosed
EP-0399519-A2 Potentiating cell-mediated immunity utilizing polyamine derivatives MERRELL PHARMACEUTICALS INC. (US) 1990-11-28 EP disclosed
EP-0277635-A2 Novel polyamine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX HDAC1 102/4885HDAC3 142/4885HDAC2 409/4885
US-20040019069-A1 Somatostatin analogue compounds SSTR2, SSTR1, SSTR4 HDAC1 1411/4885HDAC3 345/4885HDAC2 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.